Patients with multiple sclerosis in the Russian Federation complained that they could be left without therapy
[ad_1]
Russian patients with secondary progressive multiple sclerosis in 2023 may be left without therapy. The government did not include the Cayendra immunosuppressant recommended by the Ministry of Health in the list of high-cost nosologies (VZN), Izvestia writes with reference to the appeal of the All-Russian Public Organization of Disabled Persons with Multiple Sclerosis (OOOIBRS) to the head of the Ministry of Health, Mikhail Murashko.
2,000 patients have been nominated by the regions as applicants for the Cayendra drug. The drug was approved for inclusion in the VZN list in August last year.
The drug was not included in the final list approved by the government in December. Thus, the purchase of the drug will not be paid from the federal budget. This means that providing them to patients will fall on the shoulders of the regions.
In 2022, the regions were able to purchase the drug for 350 patients. The risk remains that the rest of those in need will not receive the medicine.
[ad_2]
Source link
